Pall Corp. (PLL) reports preliminary financial results for the year ended 2012-07-31.
Pall Corp. (PLL-US) recently reported its preliminary financial results based on which we provide a unique peer-based analysis of the company. CapitalCube's analysis is based on the company's performance over the last twelve months (unless stated otherwise).
Pall Corp.'s analysis versus peers uses the following peer-set: Terumo Corp.(TRUMF.PK), Mettler-Toledo International Inc. (MTD), Qiagen N.V. (QGEN), PerkinElmer Inc. (PKI), Bio-Rad Laboratories Inc. Cl A (BIO), Cepheid (CPHD), Bruker Corp. (BRKR), FEI Co. (FEIC), Hermes Microvision Inc. (HESAF.PK) and Tecan Group AG (TCHBF.PK). The table below shows the preliminary results along with the recent trend for revenues, net income and returns.
|Annual (USD million)||2012-07-31||2011-07-31||2010-07-31||2009-07-31||2008-07-31|
|Revenue Growth %||(2.5)||14.1||3.1||(9.4)||14.3|
|Net Income Growth %||(11.0)||30.8||23.3||(10.0)||70.4|
|Net Margin %||10.5||11.5||10.0||8.4||8.4|
Pall Corp. currently trades at a higher Price/Book ratio (4.5) than its peer median (3.1). PLL-US's operating performance is higher than the median of its chosen peers (ROE of 20.1% compared to the peer median ROE of 13.3%) but the market does not seem to expect higher growth relative to peers (PE of 22.8 compared to peer median of 23.4) but simply to maintain its relatively high rates of return.
The company attempts to achieve high profit margins (currently 10.8% vs. peer median of 8.9%) through differentiated products. It currently operates with peer median asset turns of 0.8x. PLL-US's net margin has declined 0.7 percentage points from last year's high but remains above its five-year average net margin of 8.8.
Changes in the company's annual top line and earnings (-2.5% and -11.0% respectively) generally lag its peers. This implies a lack of strategic focus and/or inability to execute. We view such companies as laggards relative to peers.
PLL-US's return on assets is above its peer median both in the current period (9.1% vs. peer median 5.9%) and also over the past five years (8.3% vs. peer median 5.7%). This performance suggests that the company's relatively high operating returns are sustainable.
The company's gross margin of 54.1% is around peer median suggesting that PLL-US's operations do not benefit from any differentiating pricing advantage. In addition, PLL-US's pre-tax margin of 14.2% is also around the peer median suggesting no operating cost advantage relative to peers.
Growth & Investment Strategy
While PLL-US's revenues growth has been below the peer median in the last few years (4.7% vs. 8.5% respectively for the past three years), the market still gives the stock an about peer median PE ratio of 22.8. The market seems to see the company as a long-term strategic bet.
PLL-US's annualized rate of change in capital of 6.4% over the past three years is less than its peer median of 11.4%. This investment has generated a better than peer median return on capital of 13.5% averaged over the same three years. This combination of a relatively low investment with good returns suggests that the company is likely milking its business.
PLL-US has reported relatively strong net income margin for the last twelve months (10.8% vs. peer median of 8.9%). This margin performance combined with relatively high accruals (6.3% vs. peer median of 3.5%) suggests possible conservative accounting and an understatement of its reported net income.
PLL-US's accruals over the last twelve months are positive suggesting a buildup of reserves. In addition, the level of accrual is greater than the peer median -- which suggests a relatively strong buildup in reserves compared to its peers.
Pall Corp. supplies filtration, separation and purification technologies, principally made by the company using its engineering capability and fluid management expertise, proprietary filter media, and other fluid clarification and separations equipment for the removal of solid, liquid and gaseous contaminants from a wide variety of liquids and gases. The company operates its business through two businesses: Life Sciences and Industrial. The Life Sciences business group is focused on developing, manufacturing and selling products to customers in the Medical, BioPharmaceuticals and Food & Beverage markets. The Industrial business group is focused on developing, manufacturing and selling products to customers in the Energy & Water, Aeropower and Microelectronics markets. It was founded on July 31, 1946 and is headquartered in Port Washington, NY.
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party's use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you're agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website analytixinsight.com.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.